摘要
目的探讨丹参注射液联合多巴胺与利尿剂治疗肝硬化合并腹腔积液的临床疗效。方法选择医院2012年5月至2014年4月收治的肝硬化腹腔积液患者86例,按随机数字表法分为研究组和对照组,各43例。研究组联用丹参注射液及多巴胺与利尿剂(呋塞米),对照组仅给予多巴胺与呋塞米,两组均治疗3个月。结果研究组总有效率为86.05%,明显高于对照组的46.51%(P<0.05);治疗后,研究组患者丙氨酸氨基转移酶、肌酐、血尿素氮等肝功能指标及总胆红素、清蛋白、血钠、血钾等实验室各项生化指标均显著优于对照组(P<0.05);研究组患者的住院时间为(30.21±2.45)d,显著短于对照组患者的(43.41±3.66)d(t=19.45,P<0.05);研究组患者的接受度、腹腔感染情况显著优于对照组(P<0.05)。结论丹参注射液联合多巴胺与利尿剂呋塞米治疗肝硬化腹腔积液,可显著改善患者的临床表现及肝功能指标和实验室生化指标,效果确切,患者住院时间更短,接受度更高,值得临床推广。
Objective To investigate the effect of Danshen Injection combined with diuretics and dopamine in the treatment of hepatocirrhosis with seroperitoneum. Methods Totally 86 patients with hepatocirrhosis and seroperitoneum in our hospital from May 2012 to April 2014 were selected and randomly divided into the study group and the control group,43 cases in each group. The study group was given Danshen Injection combined with diuretics and dopamine（ furosemide）,while the control group was given diuretics and furosemide. The two groups were treated for 3 months. Results The total effective rate of the study group was 86. 05%,which was significantly higher than 46. 51% of the control group（ P 〈 0. 05）. After treatment,the alanine aminotransferase,creatinine,blood urea nitrogen,liver function index and total bilirubin,albumin,blood sodium,blood potassium and other laboratory biochemical indexes of the study group were significantly better than those of the control group（ P 〈 0. 05）. The hospitalization time of patients in the study group was（ 30. 21 ±2. 45） d,which was significantly shorter than（ 43. 41 ± 3. 66） d in the control group patients（ t = 19. 45,P 〈 0. 05）. The patient＇ s acceptance and abdominal infection in the study group were significantly better than those in the control group（ P 〈 0. 05）.Conclusion Danshen Injection combined with diuretics and dopamine in the treatment of hepatocirrhosis with seroperitoneum can significantly improve the patient＇s clinical manifestation and liver function indicators and laboratory biochemical indexes,the effect is accurate,the patients have shorter hospitalization time and higher acceptance,which is worthy of clinical promotion.
作者
胡绍君
骆勇
屈小平
Hu Shaojun Luo Yong Qu Xiaoping(Xinjin People＇s Hospital of Chengdu, Chengdu, Sichuan, China 611430)
出处
《中国药业》
CAS
2017年第18期37-39,共3页
China Pharmaceuticals
关键词
肝硬化
腹腔积液
呋塞米
多巴胺
丹参注射液
临床疗效
hepatocirrhosis
seroperitoneum
furosemide
dopamine
Danshen Injection
clinical effect
